Wire · opportunities
FDA set to decide on experimental DMD treatment in early 2027
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 July 2026 · Fusion42 review
FDA has agreed to review Dyne Therapeutics' z-rostudirsen, an exon-51-skipping therapy for DMD, with a decision expected by January 2027. If approved, the treatment could be commercially available within the first months of 2027.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you build DMD diagnostics, patient management software, or rehabilitation tools, you now have a six-month window to lock in relationships with neuromuscular clinics before a new standard-of-care therapy lands. Dyne's approval creates a cohort of newly treated patients who'll need monitoring, adherence tracking, and outcome data—that's your customer base.
◆ Coverage
1 source · 21 Jul 2026
◆ Related on Wire
◆ Topics